# SPINRAZA (nusinersen)
Keywords: SPINRAZA, nusinersen, spinal muscular atrophy, SMA, SMN protein, antisense oligonucleotide, 5q SMA, motor neuron loss

> SPINRAZA is a treatment for children and adults with spinal muscular atrophy (SMA), designed to address the underlying cause of the disease by increasing functional SMN protein levels. This page provides detailed information about its mechanism of action, safety, dosing, and clinical studies.

## Details
- [Mechanism of Action](#): Explains how SPINRAZA increases functional SMN protein by targeting SMN2 pre-mRNA to retain exon 7.
- [Safety](#): Provides safety information and considerations for SPINRAZA treatment.
- [Dosing Overview](#): Details the dosing regimen and administration guidelines for SPINRAZA.
- [Administration](#): Describes the process for administering SPINRAZA to patients.
- [Product Characteristics](#): Summarizes the key characteristics of SPINRAZA as a treatment.
- [Clinical Study Programme](#): Highlights results from multiple clinical trials and studies on SPINRAZA.
- [Who Could Benefit from SPINRAZA?](#): Identifies patients who may benefit from SPINRAZA treatment.
- [SPINRAZA Access](#): Information on accessing SPINRAZA treatment centers and services.
- [FAQs](#): Frequently asked questions about SPINRAZA.
- [HFMSE Scale](#): Overview of the HFMSE scale used to assess motor function in SMA patients.
- [Experience the Everyday](#): Features real-life patient experiences with SMA and SPINRAZA treatment.